First Patient Dosed With CX-801 Plus Keytruda in Metastatic Melanoma
The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma, aiming to assess safety and early antitumor activity.
First Patient With Advanced Lung Cancer Dosed With Peluntamig Combo
The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.
